Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, Galina Lukina, Merete Lund Hetland, Ulrik Tarp, Cem Gabay, Piet L C M van Riel, Dan C Nordström, Juan Gomez-Reino, Karel Pavelka, Matija Tomsic, Tore K Kvien, Ronald F van Vollenhoven

    213 Citationer (Scopus)

    Abstract

    To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response.
    OriginalsprogEngelsk
    TidsskriftAnnals of the Rheumatic Diseases
    Vol/bind70
    Udgave nummer9
    Sider (fra-til)1575-1580
    Antal sider6
    ISSN0003-4967
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries'. Sammen danner de et unikt fingeraftryk.

    Citationsformater